2026 Global: Nuclear Medicine Isotopes Market -Competitive Review (2032) report
Description
The 2026 Global: Nuclear Medicine Isotopes Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
The nuclear medicine isotopes market is dominated by a compact set of integrated producers and distributors that control essential production, supply chains, and radiopharmaceutical formulation for diagnostic imaging and targeted therapy. Lantheus Medical Imaging (HQ: North Billerica, Massachusetts, United States) is a leading US-based developer and distributor of Tc-99m–based radiopharmaceuticals and related imaging agents. Eckert & Ziegler Strahlenmedizin AG (HQ: Berlin, Germany) manufactures and distributes a range of radioisotopes and radiopharmaceutical components, including calibrated sources and therapeutic isotopes, supported by a robust European manufacturing footprint. Nordion (HQ: Ottawa, Ontario, Canada) supplies Mo-99 and other critical radiopharmaceutical materials within a broader health-science network. IBA- Ion Beam Applications (HQ: Louvain-la-Neuve, Belgium) operates a large cyclotron portfolio for PET isotope production and provides radiopharmaceuticals and services to hospitals across Europe. Jubilant Radiopharma (HQ: Noida, Uttar Pradesh, India) leverages Jubilant’s global manufacturing network to deliver radiopharmaceuticals, radiotracers, and related components in Asia and the Middle East.
Curium Pharma (HQ: Paris, France) stands as a major European radiopharmaceutical producer with manufacturing and distribution networks spanning the continent and extending to North America. Mallinckrodt Pharmaceuticals (HQ: St. Louis, Missouri, United States) operates radiopharmacy services and specialty radiopharmaceuticals, contributing to domestic and international isotope supply chains through manufacturing, packaging, and distribution capabilities. Siemens Healthineers (HQ: Erlangen, Germany) supplies imaging equipment, radiopharmaceuticals, and service networks that support PET and SPECT operations, while pursuing advances in theranostics and precision imaging. Bayer AG (HQ: Leverkusen, North Rhine-Westphalia, Germany) maintains a portfolio of radiopharmaceuticals and related isotopes, with manufacturing, regulatory, and distribution capabilities that support diagnostic and therapeutic uses. Cardinal Health (HQ: Dublin, Ohio, United States) provides broad radiopharmacy distribution, logistics, and pharmacy services that underpin hospital-based isotope administration, quality control, and inventory management. Together, these firms coordinate regulatory compliance, quality assurance, and cross-border logistics essential to continuous patient access across regions worldwide.
Collectively, these ten companies anchor the nuclear medicine isotope market, aligning production capacity with regulatory standards and quality systems for global diagnostic and therapeutic use. North American suppliers such as Lantheus, Nordion, Mallinckrodt, and Cardinal Health coordinate cross-border distribution, while European producers—Eckert & Ziegler, Curium, Siemens Healthineers, and Bayer—maintain multiple manufacturing sites and regional hubs to meet demand in the EU and beyond. Asia-focused players like Jubilant Radiopharma broaden regional access to radiopharmaceuticals, and IBA's cyclotron infrastructure supports PET traceability across Europe. The resulting ecosystem is characterized by ongoing investment in cyclotron capacity, radiopharmaceutical development, and intercompany collaboration for regulatory clearance and supply chain resilience. As clinical indications expand—from bone and neuroendocrine tumor imaging to targeted radionuclide therapy—the ten companies highlighted here will continue to drive innovation, shape pricing strategies, and influence policy debate regarding isotope sourcing, transport, and stewardship. Ongoing transparency will strengthen global security measures.
The nuclear medicine isotopes market is dominated by a compact set of integrated producers and distributors that control essential production, supply chains, and radiopharmaceutical formulation for diagnostic imaging and targeted therapy. Lantheus Medical Imaging (HQ: North Billerica, Massachusetts, United States) is a leading US-based developer and distributor of Tc-99m–based radiopharmaceuticals and related imaging agents. Eckert & Ziegler Strahlenmedizin AG (HQ: Berlin, Germany) manufactures and distributes a range of radioisotopes and radiopharmaceutical components, including calibrated sources and therapeutic isotopes, supported by a robust European manufacturing footprint. Nordion (HQ: Ottawa, Ontario, Canada) supplies Mo-99 and other critical radiopharmaceutical materials within a broader health-science network. IBA- Ion Beam Applications (HQ: Louvain-la-Neuve, Belgium) operates a large cyclotron portfolio for PET isotope production and provides radiopharmaceuticals and services to hospitals across Europe. Jubilant Radiopharma (HQ: Noida, Uttar Pradesh, India) leverages Jubilant’s global manufacturing network to deliver radiopharmaceuticals, radiotracers, and related components in Asia and the Middle East.
Curium Pharma (HQ: Paris, France) stands as a major European radiopharmaceutical producer with manufacturing and distribution networks spanning the continent and extending to North America. Mallinckrodt Pharmaceuticals (HQ: St. Louis, Missouri, United States) operates radiopharmacy services and specialty radiopharmaceuticals, contributing to domestic and international isotope supply chains through manufacturing, packaging, and distribution capabilities. Siemens Healthineers (HQ: Erlangen, Germany) supplies imaging equipment, radiopharmaceuticals, and service networks that support PET and SPECT operations, while pursuing advances in theranostics and precision imaging. Bayer AG (HQ: Leverkusen, North Rhine-Westphalia, Germany) maintains a portfolio of radiopharmaceuticals and related isotopes, with manufacturing, regulatory, and distribution capabilities that support diagnostic and therapeutic uses. Cardinal Health (HQ: Dublin, Ohio, United States) provides broad radiopharmacy distribution, logistics, and pharmacy services that underpin hospital-based isotope administration, quality control, and inventory management. Together, these firms coordinate regulatory compliance, quality assurance, and cross-border logistics essential to continuous patient access across regions worldwide.
Collectively, these ten companies anchor the nuclear medicine isotope market, aligning production capacity with regulatory standards and quality systems for global diagnostic and therapeutic use. North American suppliers such as Lantheus, Nordion, Mallinckrodt, and Cardinal Health coordinate cross-border distribution, while European producers—Eckert & Ziegler, Curium, Siemens Healthineers, and Bayer—maintain multiple manufacturing sites and regional hubs to meet demand in the EU and beyond. Asia-focused players like Jubilant Radiopharma broaden regional access to radiopharmaceuticals, and IBA's cyclotron infrastructure supports PET traceability across Europe. The resulting ecosystem is characterized by ongoing investment in cyclotron capacity, radiopharmaceutical development, and intercompany collaboration for regulatory clearance and supply chain resilience. As clinical indications expand—from bone and neuroendocrine tumor imaging to targeted radionuclide therapy—the ten companies highlighted here will continue to drive innovation, shape pricing strategies, and influence policy debate regarding isotope sourcing, transport, and stewardship. Ongoing transparency will strengthen global security measures.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
